Japan Approves Stem Cell Therapies for Parkinson’s & Heart Disease
In a landmark achievement for regenerative medicine, Japan has approved the world’s first stem cell therapies for both Parkinson’s disease and severe heart failure. The approvals, granted on , pave the way for these innovative treatments to become available to patients in the coming months, according to Sumitomo Pharma, one of the companies involved.
The therapies, known as Amchepry for Parkinson’s disease and ReHeart for heart failure, utilize induced pluripotent stem (iPS) cells – a groundbreaking technology that allows scientists to reprogram adult cells back into a youthful, versatile state. This differs from traditional stem cell therapies that rely on embryonic stem cells. IPS cells can then be guided to develop into specific cell types needed to repair damaged tissues.
Amchepry, developed by Sumitomo Pharma and Racthera, involves transplanting these reprogrammed cells directly into the brains of patients with Parkinson’s disease. The goal is to replace the dopamine-producing neurons that are lost in the disease, thereby alleviating motor symptoms like tremors and rigidity. Initial trials have involved a small cohort of patients, with promising early results.
ReHeart, created by Cuorips, utilizes sheets of cardiac muscle cells derived from iPS cells to help restore heart function in patients with severe heart failure. The therapy aims to rebuild damaged heart tissue and improve blood flow.
The approval process involved a “conditional and time-limited” approval for manufacturing and marketing, as stated by Sumitomo Pharma. This means that while the therapies are approved for use, further studies and post-market surveillance will be required to confirm their long-term safety and efficacy. Companies will need to seek continued approval within seven years to secure full, conventional approval.
The decision follows a recommendation from an advisory panel to Japan’s health ministry and confirmation from Health, Labour and Welfare Minister Kenichiro Ueno. “I hope this will provide relief to patients not only in Japan but around the world,” Ueno stated, according to reports from Anadolu Ajansı.
The development of iPS cell technology has been a major focus of regenerative medicine research since , when Japanese scientist Shinya Yamanaka and Kazutoshi Takahashi at Kyoto University published their groundbreaking method for reprogramming adult cells. Yamanaka was awarded the Nobel Prize in 2012 for this work.
Clinical trials for Amchepry involved seven patients with Parkinson’s disease, aged between and years old. Each patient received between five and ten million cells implanted on both sides of the brain. Researchers found the treatment to be safe and showed improvements in symptoms. The iPS cells were developed into precursor cells that produce dopamine, a neurotransmitter deficient in Parkinson’s disease.
Parkinson’s disease is a progressive neurodegenerative disorder affecting over ten million people worldwide, according to the Parkinson’s Foundation. While current treatments can manage symptoms, they do not halt the disease’s progression or offer a cure. The aim of Amchepry is to improve motor skills in patients who have not responded adequately to existing therapies.
The approval of these therapies represents a significant step forward in the field of regenerative medicine, offering hope for patients with debilitating conditions. However, experts caution that further research is needed to fully understand the long-term effects and optimize the use of iPS cell-based therapies. Paul Knoepfler, a stem-cell researcher at the University of California, Davis, described the approvals as a “risky regulatory experiment,” emphasizing the need for larger trials to ensure safety and efficacy. He noted that while the data are “encouraging,” it is still early days for commercialization of such products.
The Japanese health ministry also approved ReHeart, which utilizes sheets of cardiac muscle developed by Cuorips, to aid in the formation of new blood vessels and restore cardiac function. These treatments are expected to be available to patients around mid-.